S&P revises Boston Scientific outlook to negative on franchise pressures
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- S&P Global Ratings has revised its outlook on Boston Scientific Corp. to negative from stable, warning that deepening commercial headwinds across its core product franchises will likely keep financial leverage stretched through 2028. While the rating agency…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA negative outlook signals stretched leverage and slowing growth at a large medtech company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01S&P moved the Boston Scientific outlook to negative while affirming the 'A-' rating.
- 02The agency expects revenue growth to slow to 4.4% in 2026 and 9% in 2027.
- 03The rating also reflects the balance-sheet burden of the pending $14.5 billion Penumbra acquisition.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets